ProKidney Corp. (PROK), a clinical-stage cell therapy company focused on chronic kidney disease or CKD, reported financial results for the full year 2025 and provided business highlights about its lead investigational candidate, Rilparencel or REACT. For the full year 2025, net loss attributable to...
PROKIDNEY CORP. (PROK) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's earnings totaled -$16.47 million, or -$0.12 per share. This compares with -$17.91 million, or -$0.14 per share, last year. Analysts on average had...
ProKidney Corp. (PROK), a pioneer in the treatment of chronic kidney disease, is set to present full results from its Phase 2 REGEN-007 trial as a late-breaking clinical presentation at the American Society of Nephrology (ASN) 2025 Kidney Week, taking place from November 5 to 9, 2025, in Houston, Texas. The...
ProKidney Corp. (PROK) Tuesday said it has secured alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) in patients from the ongoing Phase 3 PROACT 1 study can...
Klotho Neurosciences Inc.'s (KLTO) novel secreted-Klotho (s-KL) promoter, gene, and delivery system (KLTO-202, or s-KL-AAV.myo) has been granted Orphan Drug Designation by the FDA for the treatment of Amyotrophic Lateral Sclerosis.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.